Cargando…

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells

BACKGROUND: The current standard of care for Glioblastoma Multiforme (GBM) consists of fractionated focal irradiation with concomitant temozolomide (TMZ) chemotherapy. A promising strategy to increase the efficacy of TMZ is through interference with the DNA damage repair machinery, by poly(ADP-ribos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balvers, Rutger K, Lamfers, Martine LM, Kloezeman, Jenneke J, Kleijn, Anne, Berghauser Pont, Lotte ME, Dirven, Clemens MF, Leenstra, Sieger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359449/ https://www.ncbi.nlm.nih.gov/pubmed/25886061 http://dx.doi.org/10.1186/s12967-015-0427-y

Ejemplares similares

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity
por: Kleijn, Anne, et al.
Publicado: (2014)

Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
por: Balvers, Rutger K., et al.
Publicado: (2014)

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
por: Lemasson, Benjamin, et al.
Publicado: (2016)

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity
por: Kleijn, Anne, et al.
Publicado: (2017)

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts
por: Yuan, Alice L., et al.
Publicado: (2018)

A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells
por: Kleijn, A., et al.
Publicado: (2016)

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
por: Barazzuol, Lara, et al.
Publicado: (2013)

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2
por: Venkatesan, Subramanian, et al.
Publicado: (2016)

Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration
por: Hastings, Lyndsay, et al.
Publicado: (2022)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids
por: Somnay, Yash, et al.
Publicado: (2016)

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
por: Fratangelo, Federica, et al.
Publicado: (2018)

Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
por: Fabro, Federica, et al.
Publicado: (2022)

Currarino’s triad diagnosed in an adult woman
por: Berghauser Pont, Lotte M. E., et al.
Publicado: (2012)

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models
por: Guillot, Clément, et al.
Publicado: (2014)

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers
por: Ntafoulis, Ioannis, et al.
Publicado: (2023)

Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
por: Ntafoulis, Ioannis, et al.
Publicado: (2022)

Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888
por: Tuli, Richard, et al.
Publicado: (2014)

Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma
por: Paterniti, Irene, et al.
Publicado: (2021)

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
por: Ji, Jiuping, et al.
Publicado: (2011)

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression
por: Mariano, Germano, et al.
Publicado: (2015)

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
por: van Putten, Erik H.P., et al.
Publicado: (2022)

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
por: Munasinghe, Wijith, et al.
Publicado: (2016)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial
por: Bos, Eelke M., et al.
Publicado: (2023)

Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation
por: Reddy, Niyoti, et al.
Publicado: (2021)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures
por: Dekker, Lennard J. M., et al.
Publicado: (2022)

Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma
por: Fabro, Federica, et al.
Publicado: (2022)

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy
por: Belcaid, Zineb, et al.
Publicado: (2020)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
por: Stavrakaki, Eftychia, et al.
Publicado: (2021)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qsr1gmpb7nehnpeu7lidju8vqg